One Breath.
Could Save Your Life.
A single exhale can unlock early lung cancer detection. Our patented OneBreath™ technology delivers unmatched accuracy, non-invasive screening, and life-saving insights—all in less than 30 seconds.
The Future of Screening
With just one exhale, our technology captures biomarkers that indicate early-stage lung cancer with 94% sensitivity and 85% specificity. OneBreath™ is not just a test—it’s a promise of hope and timely care.
Precision. Accessibility.
Life-saving Impact.
Our innovative approach combines state-of-the-art microreactor chemistry with ultra-sensitive analysis.
This method turns a single breath into a powerful diagnostic snapshot that is both accurate and accessible.
Accurate Detection
Our system reliably identifies early-stage lung cancer, significantly reducing false positives compared to conventional CT scans.
Non-Invasive & Fast
No needles, radiation, or waste. Experience a painless, radiation-free screening that takes mere seconds—offering accessibility, ease, and comfort for patients.
Cost-Effective Screening
Replace expensive imaging tests with our streamlined, affordable solution, broadening access to vital early detection.
Revolutionizing Diagnostics Through —Innovation
At Breath Diagnostics, we harness the natural process of breathing to capture volatile organic compounds.
Our proprietary microreactor chemically transforms these fleeting biomarkers into quantifiable indicators of lung cancer—all without complex preparation. This simple, reliable process turns one complete exhale into precise diagnostic data, ensuring that every breath is a step toward better health.
Transforming Lung Cancer Screening
Experience a Paradigm Shift in Diagnostics with OneBreath™—where chemical innovation meets clinical precision to detect lung cancer early, safely, and cost-effectively.
Revolutionizing Breath Analysis
OneBreath™, leverages patented derivatization technology through a microreactor to capture volatile organic compounds (VOCs) in exhaled breath. Unlike traditional desorption-based breath analysis, our approach derivatizes VOCs into cationic adducts, dramatically improving mass spectrometry (MS) sensitivity. This allows us to detect trace levels of biomarkers with exceptional precision, avoiding thermal degradation or ionization inefficiencies associated with gas chromatography-mass spectrometry (GC-MS).
Proven in Over 800 Patients
Extensive clinical trials have demonstrated 94% sensitivity and 85% specificity, establishing OneBreath™ as a trusted diagnostic tool. This performance minimizes false positives and empowers timely interventions.
Affordable, Accessible, and Impactful
Designed for integration in clinics, pharmacies, and community settings, our cost-effective technology makes advanced screening available to a wider population.
By simplifying the screening process, OneBreath™ paves the way for a transformative shift in how lung cancer is detected and managed.
Core Pillars of OneBreath™
At the heart of our technology lie three foundational principles—innovation, trust, and impact. These pillars drive every breakthrough we make and guide our mission to transform early cancer detection.
Ready to Transform Lung Cancer Screening? Discover the Future Today.
Watch our video to learn how OneBreath™ is revolutionizing diagnostics with life-saving precision and simplicity.
Driving Change with Data
Our impressive clinical results and technological breakthroughs are reshaping lung cancer detection. Discover the numbers that validate our promise of early, accurate, and accessible screening.
94% Sensitivity
Reliably detects early-stage lung cancer to enable prompt intervention.
85% Specificity
Minimizes false positives and reduces unnecessary follow-up procedures.
800+ Patients
Extensive clinical trials validate our technology’s impact across diverse populations.”
Multiple Global Patents
Protected innovations that secure our leadership in diagnostic advancements.”
Frequently Asked Questions
OneBreath™ is a patented, non-invasive diagnostic tool that analyzes a single exhaled breath to detect specific volatile organic compounds (VOCs) associated with lung cancer. Our unique microreactor chemically derivatizes these compounds, which are then quantified using ultra-high-performance liquid chromatography-mass spectrometry (UHPLC-MS). This process delivers highly accurate results—capturing even trace biomarkers—without the need for radiation or invasive procedures.
Clinical trials involving over 800 patients have shown that OneBreath™ achieves 94% sensitivity and 85% specificity. These metrics compare favorably with current low-dose CT scans, significantly reducing false positives. The technology’s ability to reliably distinguish between benign and malignant conditions can give healthcare providers confidence in early diagnosis and timely treatment.
Absolutely. OneBreath™ is entirely non-invasive and requires only a single, natural breath—eliminating the need for radiation or blood draws. This simplicity not only enhances patient comfort and compliance but also makes the test safe for repeated screenings over time, ensuring ongoing monitoring without any risk.
OneBreath™ is ideal for individuals at risk of lung cancer, particularly current and former smokers and those with other risk factors. Its ease of use and rapid turnaround make it suitable for routine screenings in clinics, pharmacies, and community health centers, expanding access to early detection and ultimately saving lives.
After a breath sample is collected, it is sent to any laboratory with mass spectrometry capabilities - just like a normal blood sample. Using UHPLC, our samples can be analyzed in 10 mins. Therefore, results are available based on lab availability, allowing healthcare providers to make prompt, informed decisions about patient care. This timely turnaround is critical for early intervention and improved patient outcomes.
Unlike traditional imaging tests such as low-dose CT scans, which are expensive and expose patients to radiation, OneBreath™ offers a fast, affordable, and non-invasive alternative. Its advanced microreactor technology and UHPLC-MS analysis yield higher specificity and fewer false positives. Moreover, by simplifying the screening process to a single breath, it increases compliance and enables broader community-based deployment—revolutionizing how lung cancer is detected and managed.
The Visionaries Behind OneBreath™
Our diverse team of engineers, scientists, and medical professionals is united by a single mission—to revolutionize lung cancer detection. With decades of combined experience and a passion for innovation, our leadership drives every breakthrough at Breath Diagnostics.
Ready to Breathe New Life Into Diagnostics?
Together, we can reshape the future of healthcare. With proven technology, clinical validation, and strategic partnerships, OneBreath™ is paving the way for early detection that saves lives.